1

Charles River Laboratories

#1487

Rank

$11.46B

Marketcap

US United States

Country

Charles River Laboratories
Leadership team

Mr. James C. Foster J.D. (Chairman, CEO & Pres)

Ms. Birgit Girshick (Corp. Exec. VP & COO)

Mr. Joseph W. LaPlume (Corp. Exec. VP of Corp. Devel. & Strategy)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Wilmington, Massachusetts, United States
Established
1947
Company Registration
SEC CIK number: 0001100682
Net Income
500M - 1B
Revenue
Above - 1B
Traded as
CRL
Social Media
Overview
Location
Summary
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
History

Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-man laboratory in Boston, overlooking the Charles River. In an effort to fulfil the regional need for laboratory animal models, he bred, fed, and cared for the animals and personally delivered them to local researchers.

In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 with the opening of a new animal production facility in France.

The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. During this time, Henry and Jim Foster are still in charge of the company.

In 1988, the organization started to expand their portfolio to include the creation of transgenic mice and rats. In the 1990s, Charles River expanded their portfolio further. They purchased Specific Pathogen Antigen Free Avian Services and serologic diagnostic services Merck, Sharp, and Dohme in 1992 and started offering in vitro endotoxin testing two years later.

Between 1996 and 2000, the company acquired Endosafe, Inc., was bought back from Bausch & Lomb by Jim Foster, acquired Sierra Biomedical, expanded its portfolio to offer biopharmaceutical services, and went public on the New York Stock Exchange.

Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train their employees on the importance of animal welfare. The same year, they were named "Company of the Year" by The Boston Globe. The company then introduced preconditioning services in 2005 to provide their customers with study-ready animals.

In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.

In April 2019, Charles River announced it will be ceasing its San Diego operations, moving the work to one of its sites in Northern California. In California, the company also has sites in the town of Hollister and in South San Francisco. The work done in San Diego—the breeding of rodents that scientists use to test compounds—was moved to Hollister, California.The chairman and chief executive officer is James C. Foster, the son of founder Henry Foster.

In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M USD.

Mission
Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.
Vision
We’re committed to helping our customers bring better treatments to patients faster through our customizable models, unique services and expert support.
Key Team

Mr. William D. Barbo (Chief Commercial Officer & Corp. Exec. VP)

Mr. David Ross Smith (Sr. Financial Advisor)

Ms. Flavia H. Pease (Corp. Exec. VP & CFO)

Mr. Michael Gunnar Knell (Corp. Sr. VP & Chief Accounting Officer)

Prof. Julie Frearson Ph.D. (Corp. Sr. VP & Chief Scientific Officer)

Mr. Mark Mintz (Corp. Sr. VP & Chief Information Officer)

Todd Spencer (Corp. VP of Investor Relations)

Recognition and Awards
Charles River Laboratories International, Inc. has been recognized with numerous awards and accolades ranging from Forbes Magazine’s “Best Small Companies in America” to Great Place to Work®’s “100 Best Companies” to Top Rated Employers’ “Employer of Choice.”
References
Charles River Laboratories
Leadership team

Mr. James C. Foster J.D. (Chairman, CEO & Pres)

Ms. Birgit Girshick (Corp. Exec. VP & COO)

Mr. Joseph W. LaPlume (Corp. Exec. VP of Corp. Devel. & Strategy)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Wilmington, Massachusetts, United States
Established
1947
Company Registration
SEC CIK number: 0001100682
Net Income
500M - 1B
Revenue
Above - 1B
Traded as
CRL
Social Media